Medtronic Announces CE Mark for Recapturable CoreValve Evolute R System
Next-Generation TAVI System Offers Ability to Recapture and Reposition During Deployment
MINNEAPOLIS – Sept. 3, 2014 – Medtronic, Inc. announced CE (Conformité Européene) Mark for the 23 mm CoreValve® Evolut™ R System for transcatheter aortic valve implantation (TAVI). The novel, self-expanding valve and 14 French (Fr) equivalent delivery system offers new capabilities that advance valve performance and deliverability during the procedure, while providing the option to recapture (re-sheath the valve back into the catheter) and reposition (move the valve to a new position either above or below its current placement) the valve during deployment phase, if needed.
“The CoreValve Evolut R System offers improvements to a proven TAVI technology platform,” said Eberhard Grube, MD, head, Center of Innovative Interventions in Cardiology (CIIC), University Hospital Bonn, Germany. “The system’s new recapture-enabled capabilities and advancements in valve delivery provide physicians with added procedural confidence. It’s a significant advance to know there is the option to redeploy the valve in the ideal position if necessary.”
The novel system consisting of the CoreValve Evolut R transcatheter aortic valve and the EnVeo™ R Delivery Catheter System is designed for first-time positioning accuracy and also offers a new InLine™ Sheath that significantly reduces the profile to the lowest on the market (14 Fr equivalent, less than 1/5 inch); a smaller profile size is believed to minimize the risk of major vascular complications. The new valve is anatomically designed to increase conformability at the annulus for optimal annular fit and sealing, while maintaining supra-annular valve position for improved hemodynamic performance.
The 23 mm CoreValve Evolut R transcatheter valve and the CoreValve EnVeo R Delivery Catheter System are now available in Europe and other countries that recognize the CE mark. It is not approved for commercial use in the United States, where it is currently undergoing clinical trials.